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PURPOSE: To study the effect of antiretroviral drugs administered during pregnancy on CD4 lymphocyte counts and HIV-
1 RNA levels of pregnant women and on the anthropometric parameters of their neonates.
METHODS: A prospective study was conducted on 57 pregnant women and their neonates divided into 3 groups: ZDV
Group, HIV-infected mothers taking zidovudine (n = 20); triple therapy (TT) Group, mothers taking zidovudine + lamivudine
+ nelfinavir (n = 25), and Control Group, normal women (n = 12). CD4 lymphocyte counts and HIV-1 RNA levels of pregnant
women were analyzed during two periods of pregnancy. The perinatal prognosis took into account preterm rates, birth
weight, intrauterine growth restriction, perinatal death, and vertical transmission of HIV-1. Data were analyzed statistically
using the nonparametric chi-square, Mann-Whitney, Friedman, Kruskal-Wallis, and Wilcoxon matched pairs tests, with the
level of significance set at P <.05.
RESULTS: The major maternal demographic and anthropometric data were homogeneous for the various groups. HIV-1
viral burden, which was initially elevated, median of 14,370 copies/mL, was significantly reduced in the TT group, reaching
40 copies/mL. With respect to T-CD4+ lymphocyte counts, there was a significant recovery in Group TT at the end of
pregnancy, this value being significantly different from that for the ZDV group (P =.0052). There was no difference between
groups regarding gestation length, Apgar scores, or neonatal anthropometric classification. There was no case of vertical
HIV-1 transmission.
CONCLUSIONS: The results obtained for the present series demonstrate the efficiency and suggest safety of the use of
antiretroviral drugs during pregnancy as revealed by anthropometric parameters of the neonate.
KEYWORDS: Antiretroviral. HIV. Pregnancy. Neonate. Prognosis.
Within the epidemiologic context of HIV-1 infection,
women may be considered the main victims of the sexual
dissemination of this viral disease and are currently present-
ing high seroconversion rates as recorded by the Ministry
of Health of Brazil.1 However, the improved quality of life
and survival of HIV-1-infected patients, together with the
significant reduction of vertical transmission obtained af-
ter a better understanding of the pathogenesis and risk fac-
tors for the disease and after the introduction of powerful
antiretroviral (ARV) medications, has eliminated the con-
dition of HIV-1 infection as an insurmountable obstacle re-
garding maternity.2
Antiretroviral compounds differ from most other new
pharmaceutical agents in that they have become widely pre-
scribed in pregnancy in the absence of proof of safety.3 Com-
binations of 3 or more compounds are recommended when
treatment of the mother is deemed necessary because of ad-
vanced HIV infection. Although many thousands of women
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have taken ARV drugs to reduce the risk of transmission,
documented experience in human pregnancy remains sadly
lacking, with the possible exception of zidovudine (ZDV),
which has been prescribed in clinical trials to several hun-
dred mother-infant pairs.4
In spite of the wealth of reports available regarding the
adverse effects of ARV drugs in adults, there is a scarcity of
national, prospective, or longitudinal studies emphasizing
these results in pregnant women who use these drugs or of
studies on the effects of ARV drugs on perinatal prognosis.
In the present series, we evaluated the effects of two differ-
ent intrauterine exposures, prophylactic use of ZDV or tri-
ple ARV treatment (zidovudine + lamivudine + nelfinavir)
on CD4 lymphocyte counts and HIV-1 RNA levels of preg-
nant women and on the anthropometric parameters of the
neonate.
METHOD
The study was approved by the Research Ethics Com-
mittee of the Institution, and signed informed consent form
to participate was obtained from each subject. The prospec-
tive study was conducted from September 2001 to March
2003 on 57 women aged 16 to 43 years with singleton
gestations. Forty-five of these women were infected with
HIV-1, and the remaining 12 were normal in both clinical
and laboratory terms and were selected when they started
prenatal care.
The women were considered infected with HIV-1 when
two different serum samples were found to be positive for
HIV-1 antibodies by ELISA and confirmed by the Western
blot test. Only HIV-infected patients who had not been
treated previously with ARV drugs were selected for the
study.
The HIV-1–infected women were divided into 2 groups:
ZDV Group and triple treatment (TT) Group. The ZDV
Group consisted of 20 pregnant women who fulfilled the
requirements for the prophylactic use of ZDV (CD4 >500
cells/mm3 and viral load <1,000 copies/mL). The TT Group
consisted of 25 pregnant women with a clinical and labo-
ratory indication (CD4 <500 cells/mm3) for triple ARV treat-
ment (zidovudine + lamivudine + nelfinavir) according to
the criteria established by the Perinatal HIV Guidelines
Working Group Members regarding ARV treatment of preg-
nant women.5
Antiretroviral agents recommended, from the 14th week,
were zidovudine, 300 mg/dose, twice a day for the ZDV
Group, and 300 mg zidovudine, 150 mg lamivudine, and
1250 mg nelfinavir in 2 daily doses for the TT Group.
Exclusion criteria were women with renal and hepatic
insufficiency, women with a personal or first-degree rela-
tive with a history of diabetes mellitus, women with an ini-
tial body mass index (BMI) of more than 30 kg/m2, preg-
nant women with predictors of recurrent gestational diabe-
tes mellitus (GDM) such as the presence of spontaneous
abortions, major congenital malformations, stillbirth, or
macrosomia in their previous pregnancies, women who did
not comply with the use of ARV drugs or used them irregu-
larly, and women taking other medications of known dia-
betogenic effect. CD4 lymphocyte counts were analyzed by
flux cytometry, and HIV-1 RNA levels were determined by
the ultrasensitive third-generation bDNA assay (Bayer Cor-
poration, Diagnostics Division, Norwood, Mass.) conducted
according to the manufacturer’s instructions in HIV preg-
nant women. Additionally, BMI, weight gain during preg-
nancy, clinical and obstetrical interfering events, gestational
age at delivery (determined by an obstetric ultras-
sonography at the moment of the enrollment for all preg-
nant women), Apgar score, neonatal anthropometric evalu-
ation (birth weight, head circumference, crown-heel length,
standards of fetal growth according to Lubchenco et al.6),
and vertical transmission of HIV-1 were determined.
The variabilities of plasma CD4 lymphocyte counts, HIV-
1 RNA levels, and neonatal anthropometric evaluations
were calculated on the basis of the median and interquartile
variation (1st and 3rd quartile, respectively). The non-
parametric chi-square, Mann-Whitney Kruskal-Wallis, and
Wilcoxon matched pairs tests were used, with the level of
significance set at P <.05. All analyses were performed us-
ing the SPSS 10.0 software.
RESULTS
Median maternal age was 22.5 years with an
interquartile (IQ) variation of 6 years for the Control Group,
24 years (7 years) for the ZDV Group, and 27 years (6 years)
for the TT group, with no statistical difference between
groups (P = .13, Kruskal-Wallis test). Race distribution
(white and non-white) was also uniform in the three groups
(P = .14, chi-square test). Smoking habit data also did not
differ significantly between groups (P = .10, chi-square test).
Initial BMI, BMI at the end of pregnancy, and maternal
weight gain from the beginning of prenatal care to deliv-
ery was, respectively, 21.95, 25.57, and 10.5 (median val-
ues) for the pregnant women in the Control Group. No dif-
ferences were observed with respect to these variables
among the three groups (P = .10, Kruskal-Wallis test).
As expected, HIV-1 viral burden, which was initially el-
evated (14,370 copies/mL), was significantly reduced in the
TT group, reaching 40 copies/mL. The difference between
the ZDV and TT groups was significant (P <.001, Mann-
Whitney test). With respect to T-CD4+ lymphocyte counts,
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there was a significant recovery in Group TT from an ini-
tial median value of 399 cells/mL to 543 cells/ml at the
end of pregnancy, this value being significantly different
from that for the ZDV group (P =.0052, Mann-Whitney test)
(Table 1).
The median gestational age at delivery did not differ
among groups: 39 weeks for the Control Group, 38.1 weeks
for the ZDV Group, and 38.5 weeks for the TT Group (P =
.57, Kruskal-Wallis test) (Table 1). Median neonatal weight
also did not differ among groups: 3.250, 3.080 and 3.100
kg for the Control, ZDV, and TT groups, respectively (P =
.45, Kruskal-Wallis test). Analysis of these variables, of the
Apgar score, and of adequacy of anthropometric classifica-
tion did not show any significant differences among the
newborns of the various groups (P = .59, chi-square test).
There was no case of vertical transmission of HIV-1.
DISCUSSION
There is no doubt that prophylaxis with the exclusive
use of ZDV has reduced the risk of perinatal transmission
of HIV-1. However, when the mother is in an advanced
phase of infection, the use of ZDV is considered to be in-
sufficient both for maternal treatment and for the preven-
tion of vertical HIV-1 transmission. In these cases, the use
of schemes containing a combination of ARV drugs is the
most appropriate option. This option has been consistently
found to be associated with reduced HIV-1 RNA copies in
plasma and with the objective improvement of immunologic
markers, which reflect the undeniable and favorable clini-
cal readaptation of these patients.7 The ARV combination
currently used involves two nucleoside analogues and a
protease inhibitor. According to CDC data,4 nelfinavir is
preferred among protease inhibitors because of its reduced
number of side effects for the mother and because of the B
categorization assigned to it by the Food and Drug Admin-
istration (FDA).
Studies about determinants of viral load and CD4
lymphocyte counts in Brazilian HIV-infected pregnant
women making use of ARV therapy are still relatively
scarce. Two studies in Brazil have addressed these questions.
One examined the safety and feasibility of the administra-
tion of AZT/3TC combination to infected pregnant women
and their infants in Rio de Janeiro.8 Another evaluated peri-
natal HIV-1 transmission among low-income women par-
ticipants in a cohort study in Southern Brazil.9 Several dif-
ferences among these studies and the present series should
be noted: the first study did not include an evaluation of a
group taking combination ARV therapy with a protease in-
hibitor like nelfinavir; in the second study, HIV viral bur-
den and immunologic parameters were analyzed during the
inclusion period, but they were not re-evaluated near the
delivery. Recent regulations regarding the management of
HIV-1-infected pregnant women consider viral suppression
in plasma during gestation and especially during the pe-
riod immediately preceding delivery to be the primary ob-
jective in the care for these women.4 In the series reported
here, which was managed according to these guidelines, the
use of ARV drugs, particularly in the group treated with a
scheme in combination with a protease inhibitor, led to a
significant improvement in CD4 lymphocyte counts and a
Table 1 - HIV-1 viral burden (VB) and T-CD4+ lymphocyte counts of HIV-infected pregnant women in two different periods
during pregnancy.
Group 1st VB 2nd VB P 1st TCD4 2nd TCD4 P
copies/mL copies/mL cells/mm3 cells/mm3
ZDV 860 278 692 660
n=20 (600-3.400) (40-2.923) .03b (502-895) (574-862) .50
TT 14.370 40 399 543
n=25 (6.726-45.610) (40-1.499) <.001b (297-494) (377-689) <.001b
P <.001a .38 <.001 .0052a
a P <.05, ZDV Group X TT Group, Mann-Whitney test; b P <.05, First and second evaluation during pregnancy, Wilcoxon matched pairs test. Data
are reported as medians and 1st and 3rd quartiles; 1st VB and 1st TCD4 = Performed between 14-20 weeks; 2nd VB and 2nd TCD4 = Performed
between 33-38 weeks
Table 2 - Gestational age (GA), weight, head circumference
(HC), body lengths, and adequacy of anthropometric
classification (AAC) from the newborn at the time of delivery.
Group Control ZDV TT P*
n = 12 n = 20 n = 25
GA 39.0 38.1 38.5 .57
(weeks) 38.0-39.2 37.5-40.0 38.0-39.5
Weight 3.250 3.080 3.100 .45
(kg) 2.920-3.408 2.795-3.260 2.778-3.300
HC 35.2 35.0 35.0 .64
(cm) 34.5-36.0 34.0-35.7 34.2-35.5
Length 49.7 48.2 49.0 .40
(cm) 48.5-51.2 47.2-50.5 48.0-51.0
AAC 100% 95% 92% .59**
* Kruskal-Wallis test; **chi-square test; Data are presented as
median values and interquartile range.
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marked reduction of HIV-1 RNA copies in all pregnant
women. Undetectable viral load levels were obtained for
64% of these women in a prospective evaluation from the
33rd to the 38th week of pregnancy. These results are in ac-
cordance with those of authors who have observed that the
viral load decreases in HIV-positive adults receiving ARV
therapy as the adherence level increases.10 However, there
are still persistent doubts about the use of combined ARV
therapy during pregnancy, with emphasis on repercussions
of protease inhibitors on the fetus.4,11
Despite the vast literature available about the adverse
effects of protease inhibitors in adults, there is a scarcity of
national, prospective, and longitudinal studies emphasiz-
ing these results during gestation.
In recent years there has been widespread interest in peri-
natal biology. Accurate knowledge of fetal growth is im-
perative in clinical management, since growth retardation
puts the fetus at increased risk of death and/or neurologi-
cal damage.12 There is a need for parameters of intrauterine
growth that are reliable and applicable to each particular
population. Since no study in Brazil regarding standards
of fetal growth in HIV-infected women taking ARV drugs
during pregnancy has addressed this question, the present
series may be considered original. In this context, evalua-
tion of neonatal weight and anthropometric classifications
obtained for the present series supported previous reports
demonstrating that ZDV therapy does not compromise fe-
tal growth rates (weight, length and skull circumference)
compared to control groups.7,8 In addition, no difference
was observed between the Control and TT groups. Whereas
infection with HIV is associated with significant decrements
across all standardized growth outcome parameters, HIV-
uninfected infants usually do not show depressed results
regarding anthropometric parameters. These important data
may be viewed as an early indicator of HIV status.13-17 Re-
sults reported here in uninfected infants exposed to ARV
drugs during gestation are similar to those of another study
that analyzed normal newborns in Brazil.12
In the present series, there was no difference in gesta-
tional age at delivery or in 1st and 5th minute Apgar scores
among the neonates of the groups under study compared
to the Control Group. These data agree with those obtained
in the PACTG 076 study and in the meta-analysis of 2,123
pregnant women, 1,590 of whom were taking
monoprophylaxis, 396 were taking combined therapy with
no protease inhibitors, and 137 were taking combined
therapy with protease inhibitors during the period from
1990 to 1998. When these women were compared to 1,143
pregnant women who did not receive ARV drugs, it was
demonstrated that the gestational prognosis of mothers tak-
ing ZDV as monoprophylaxis during the prenatal period was
not compromised. There was no evidence that ARV drugs
affected the incidence of preterm delivery or increased low
birth weight rates, Apgar scores, or fetal mortality.18,19
In the present series, the resolution of pregnancy oc-
curred after 38.5 weeks among the patients taking an ARV
scheme containing a protease inhibitor, with no difference
from the other groups, including the Control Group. These
results are in accordance with those obtained in the PACTG
367, an observational study involving 1,472 HIV-1–infected
pregnant women, 1,150 of them treated with a combined
scheme, in which no association was observed between the
use of these medications and preterm deliveries.4
The highest preterm delivery rates observed in the
PACTG 367 involved women who had not received any
ARV medications, in agreement with studies reporting
higher rates of preterm deliveries among HIV-1–infected
women who received no treatment.20-24
In the PACTG 185, 14% of the pregnant women under-
went combined treatment with ARV drugs and presented
gestational prognoses similar to those of HIV-1–infected
women regardless of the use of ARV drugs or to those of
uninfected women after controlling for smoking and drink-
ing habits.25 In 2000, the European Collaborative Study
evaluated 3,920 mothers and their newborn infants and de-
tected a 2.6-fold higher risk of preterm delivery among
mothers who had used combined schemes before pregnancy
compared to the group that started treatment with these
schemes in the third trimester of gestation. Among the vari-
ables involved, CD4 lymphocyte counts and the use of in-
jectable drugs were more prevalent in the group of women
with preterm delivery.26 In another study on 445 pregnant
women treated with a scheme containing ZDV and 3TC, the
rate of preterm deliveries was 6%, similar to the 9% value
observed for women taking exclusively ZDV.27 However, in
the European Collaborative study,28 even after potentially
confounding variables regarding preterm delivery had been
excluded, such as the use of drugs and the stage of mater-
nal disease, a higher association was observed between the
use of ARV medication (with or without protease inhibi-
tors) and a higher rate of preterm deliveries.
Even though the results of the present series support the
safety of the use of two schemes of ARV therapy during preg-
nancy—i.e., ZDV prophylaxis and combination of ARV
agents (ZDV, lamivudine, and nelfinavir)—a limitation ex-
ists, based on the low power of the study reported here for
detecting an effect of lower magnitude among groups.
An epidemiologic evaluation conducted in the US from
January 1990 to June 2000 revealed maternal-fetal trans-
mission of HIV-1 in 20% of the women who had not re-
ceived ARV medication during pregnancy, in 10.4% of those
who had taken ZDV only, in 3.8% of those who had re-
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ceived combined therapy without a protease inhibitor, and
in 1.2% of those who had received combined schemes con-
taining a protease inhibitor.29 In the present series, no case
of perinatal transmission was observed, perhaps owing to
the care taken to support adherence to prophylactic meas-
ures or due to the limited number of cases studied.
Prophylaxis with ZDV has been implicated, although
without proof, in changes in the neurologic and cognitive
development of children exposed to HIV but not infected
with the virus.30 On the basis of data reported for children
exposed to HIV but not infected followed up in the
multicenter PACTG 076 study for a mean period of 4.2 years,
(range: 3.2-5.6 years), no difference in neurologic, cognitive,
or behavioral development was observed compared to the
control group.13 However, even more limited are the data re-
garding the potential toxicity to infants whose mothers had
received combined schemes containing a protease inhibitor
during pregnancy.3,4,11,31 In a meta-analysis involving 7 clini-
cal studies conducted on a total of 2,123 HIV-infected preg-
nant women who delivered between 1990 and 1998 and who
had received ARV therapy during the prenatal period and on
1,143 women who did not receive ARV therapy during preg-
nancy (ZDV alone in 1590 cases, combined therapy without
protease inhibitors in 396 cases, and combined therapy with
protease inhibitors in 137 cases), the use of ARV medications
was not associated with lower Apgar scores or increased fe-
tal death compared to untreated women or women taking
ZDV alone.18 These reports are similar to data demonstrated
in the present series in which no difference was observed
among treated and control groups.
The results obtained in the present series demonstrate the
efficacy of ARV agents in terms improvement on CD4
lymphocyte count, reduction in HIV viral load, and conse-
quently on vertical transmission rates. The improvement of
immunologic markers was higher for the TT Group. In addi-
tion, the present study suggests that the use of ZDV prophy-
laxis and ARV drugs, especially with the combined scheme
containing nelfinavir as a protease inhibitor, is safe during
pregnancy based on gestational age at delivery, Apgar score,
and anthropometric parameters of the neonate. On the other
hand, it is the gold standard to conduct follow-up of chil-
dren with intrauterine ARV drug exposure into adulthood
because of concerns regarding potential for adverse meta-
bolic effect of combined scheme with protease inhibitors.31
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RESUMO
El Beitune P, Duarte G, Machado AA, Quintana SM, Figueiró-
Filho EA, Abduch R. Efeito das drogas anti-retrovirais sobre
os valores dos linfócitos TCD4, RNA do HIV-1 e parâmetros
antropométricos de neonatos de gestantes portadoras do HIV-
1. Clinics. 2005;60(3):207-12.
OBJETIVOS: Estudar o efeito das drogas anti-retrovirais
sobre a quantificação dos linfócitos TCD4 e RNA do HIV-1
de gestantes portadoras do HIV-1 e parâmetros
antropométricos de seus neonatos.
MÉTODOS: Estudo prospectivo avaliando 57 gestantes e
seus neonatos em três grupos: Grupo AZT, gestantes porta-
doras do HIV utilizando zidovudina (n=20); Grupo TT,
mães utilizando zidovudina+lamivudina+nelfinavir (n=25),
e Grupo Controle, mulheres saudáveis (n=12). A quantifi-
cação dos linfócitos TCD4 e RNA do HIV-1 de gestantes
portadoras do HIV foi analisada em dois períodos durante
a gestação. O prognóstico perinatal levou em consideração
as taxas de pré-termos, restrição de crescimento intra-útero,
mortalidade perinatal e transmissão vertical do HIV-1. Os
dados foram analisados utilizando-se testes não paramé-
tricos de qui-quadrado, Mann-Whitney, Friedman, Kruskal-
Wallys e Wilcoxon para amostras pareadas, considerando-
se significativos valores associados a p<0,05.
RESULTADOS: Observou-se homogeneidade entre os da-
dos demográficos e antropométricos de realce. A carga viral,
inicialmente elevada (14.370 cópias/ml), reduziu-se signi-
ficativamente no grupo com tratamento tríplice , chegando
a 40 cópias/ml. Quanto à contagem de linfócitos CD4, ob-
servou-se recuperação significativa nas pacientes do grupo
TT, no final da gestação, sendo esse valor significativamen-
te diferente em comparação ao grupo AZT (p = 0,0052). Não
se observou diferença entre os grupos quanto à duração da
gestação, aos índices de Apgar, e à classificação
antropométrica neonatal. Não houve nenhum caso de trans-
missão vertical do HIV-1.
CONCLUSÕES: Os resultados obtidos na presente
casuística demonstram eficiência e sugerem segurança no
uso de anti-retrovirais na gestação sobre parâmetros
antropométricos dos neonatos.
UNITERMOS: Antiretroviral. HIV. Gestação. Neonato.
Prognóstico.
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